Product Description
GB08 injection is the company's first self-developed Class I innovative drug. It is an Fc fusion protein long-lasting growth hormone independently developed by the company according to clinical patient needs and based on growth hormone deficiency in children. (Sourced from: https://www.moomoo.com/news/post/38628410/kexon-pharmaceuticals-688136-sh-obtained-gb08-notice-of-approval-for?level=1&data_ticket=1718216755827869)
Mechanisms of Action: gH Replacer
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shenzhen Sinovac Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Hypopituitarism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20241992 | P1 |
Unknown |
Hypopituitarism |
None |